Comparison

Saxenda (Liraglutide) vs Wegovy (Semaglutide)

Saxenda (liraglutide 3.0 mg) and Wegovy (semaglutide 2.4 mg) are both FDA-approved once-daily and once-weekly GLP-1 receptor agonist injections respectively for chronic weight management in adults. Wegovy is clearly more effective — producing approximately 14.9% average body weight loss vs Saxenda's 5–8%, requires only once-weekly dosing, and has proven cardiovascular benefit from SELECT. Saxenda offers a longer track record (approved 2014 vs 2021) and is often considered a "stepping stone" for patients new to GLP-1 therapy. As of 2026, Wegovy is generally preferred by clinical guidelines for patients without contraindications.

4.3(112 ratings)

Quick Answer

Wegovy (semaglutide 2.4 mg weekly) outperforms Saxenda (liraglutide 3.0 mg daily) on almost every clinical measure: ~14.9% body weight loss vs ~5–8%, once-weekly vs daily dosing, and proven 20% cardiovascular event reduction (SELECT trial). Saxenda has been on the market since 2014 vs 2021 for Wegovy, offering a longer safety record and often better insurance coverage. For new starts, Wegovy is the preferred GLP-1 for weight loss when available and tolerated. Saxenda may suit patients who have failed Wegovy or need a daily-dose option.

Head-to-Head Comparison

Criteria	Saxenda (Liraglutide)	Wegovy (Semaglutide)
Active ingredient	Liraglutide 3.0 mg — GLP-1 receptor agonist	Semaglutide 2.4 mg — GLP-1 receptor agonist
FDA approval for obesity	December 2014 (pediatric: Dec 2020 for ages 12+)	June 2021 (pediatric: Dec 2022 for ages 12+)
Dosing frequency	Once daily subcutaneous injection (major adherence burden)	Once weekly subcutaneous injection
Average weight loss (pivotal trial)	~5–8% body weight at 56 weeks (SCALE Obesity, liraglutide 3.0 mg)	~14.9% body weight at 68 weeks (STEP-1, semaglutide 2.4 mg)
Dose titration	0.6 mg/day → escalate by 0.6 mg weekly → 3.0 mg target over 5 weeks	0.25 mg/week → escalate every 4 weeks → 2.4 mg target over 16–20 weeks
Nausea incidence	~39% in SCALE Obesity at 3.0 mg	~44% in STEP-1 at 2.4 mg — comparable GI profile
Cardiovascular outcomes	LEADER trial: 13% MACE reduction in T2D patients (liraglutide 1.8 mg dose)	SELECT trial: 20% MACE reduction in patients with obesity and established CVD
Half-life	~13 hours (requires daily dosing)	~7 days (enables weekly dosing)
Approval for children	Ages 12+ with obesity (BMI ≥ 30 kg/m² or 95th percentile)	Ages 12+ with obesity or overweight + weight-related comorbidity
US list price (2026)	~$1,400/month (Saxenda)	~$1,349–$1,430/month (Wegovy)
Manufacturer savings program	Novo Nordisk Saxenda savings card; reduced rates for eligible patients	Novo Nordisk Wegovy savings card: commercially insured may pay $0/month
Compounded alternative	Compounded liraglutide rarely available	Compounded semaglutide in legal gray area post-FDA shortage removal

When to Choose Each

Choose Saxenda (Liraglutide)

Patients who have tried Wegovy and need an alternative GLP-1 approach, those in healthcare systems with better Saxenda formulary coverage, pediatric patients where longer safety follow-up is valued, or patients who prefer the shorter half-life (daily drug for easier discontinuation if side effects occur).

Choose Wegovy (Semaglutide)

Most adults starting GLP-1 therapy for weight management who can access it — superior efficacy (~15% weight loss), once-weekly convenience, proven cardiovascular benefit (SELECT), and manufacturer savings programs make Wegovy the preferred first-line option for obesity pharmacotherapy.

Verdict

Wegovy is the clinically superior choice for most patients starting weight management pharmacotherapy in 2026. It produces approximately twice to three times more weight loss than Saxenda, requires only weekly rather than daily injections, and has proven 20% cardiovascular event reduction in the SELECT trial. Clinical guidelines from the ADA and Obesity Medicine Association increasingly position once-weekly GLP-1 agonists (semaglutide, tirzepatide) as first-line agents. Saxenda remains a legitimate option for patients who have tried and failed Wegovy, who need a pediatric option with longer follow-up data, or in healthcare systems where Saxenda has better formulary access. The daily injection burden of Saxenda is a meaningful practical disadvantage for most patients.

References

Liraglutide and body weight in patients with overweight or obesity (SCALE Obesity) (2015) — PubMed
Once-weekly semaglutide in adults with overweight or obesity (STEP 1) (2021) — PubMed
Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER) (2016) — PubMed
Semaglutide and cardiovascular outcomes in patients with overweight or obesity (SELECT) (2023) — PubMed
Liraglutide 3.0 mg for weight management: a 5-year randomized controlled trial (SCALE Obesity long-term) (2022) — PubMed
Two-year effects of semaglutide in adults with overweight or obesity (STEP 5) (2022) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Henry Meds

Most Peptides

4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider

✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available

✓Repair peptides including BPC-157 and TB-500

✗Higher starting price due to comprehensive programs

✗More complex onboarding including lab work requirements

Ro Body

Best Value

4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo

✓Dedicated health coach included in program

✓Strong clinical protocols with lab-work integration

✗Narrower peptide offering — GLP-1s only

✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage

✓Evidence-based one-year program with structured milestones

✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)

✗Annual program commitment required

✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees

✓Strong community and peer support features

✓Certified health coaches with regular check-ins

✗Medication billed separately from program fee — total cost can be higher

✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Frequently Asked Questions

Which causes more weight loss — Saxenda or Wegovy?

Wegovy produces substantially more weight loss than Saxenda. In pivotal obesity trials, Wegovy (semaglutide 2.4 mg weekly) produced approximately 14.9% average body weight loss at 68 weeks (STEP-1), while Saxenda (liraglutide 3.0 mg daily) produced approximately 5–8% weight loss at 56 weeks (SCALE Obesity). This reflects the higher potency of semaglutide compared to liraglutide as GLP-1 receptor agonists, as well as the higher doses used in the obesity-specific formulations. Individual responses vary, and some patients respond better to Saxenda than expected.

Which is easier to take — Saxenda or Wegovy?

Wegovy is significantly more convenient — once weekly vs once daily. For most patients, daily injections (Saxenda) create a substantially higher adherence burden than weekly injections (Wegovy). Missing doses is more consequential for daily drugs. The difference in dosing frequency is often the deciding practical factor for patients who are injection-averse. Both drugs use similar subcutaneous injection technique into the abdomen, thigh, or upper arm.

Does Saxenda or Wegovy have better cardiovascular benefit?

Both have cardiovascular outcome trial data, but at different doses. The LEADER trial showed liraglutide 1.8 mg (Victoza, T2D dose — not the Saxenda 3.0 mg dose) reduced MACE by 13% in T2D patients with high cardiovascular risk. The SELECT trial showed semaglutide 2.4 mg (Wegovy, obesity dose) reduced MACE by 20% in patients with obesity and established cardiovascular disease. Wegovy has the more directly applicable CV benefit data for obesity patients.

Can I switch from Saxenda to Wegovy?

Yes, switching is common and clinically straightforward. Many patients who achieve partial results on Saxenda transition to Wegovy for greater weight loss. The transition typically involves stopping Saxenda and starting Wegovy at 0.25 mg weekly for 4 weeks before titrating up. Because semaglutide is more potent, some patients experience a reset of GI side effects when starting Wegovy — slow titration helps manage this. Always coordinate the switch with your prescribing provider.

Which drug is older — Saxenda or Wegovy?

Saxenda was approved first — FDA approved liraglutide 3.0 mg for obesity in December 2014, giving it approximately 7 years more real-world safety data than Wegovy (approved June 2021). Saxenda's active ingredient liraglutide has been used in diabetes (Victoza) since 2010, making its safety profile even more established. This longer track record is a meaningful consideration for some clinicians, particularly in challenging patient populations.

Which is cheaper — Saxenda or Wegovy?

At 2026 US list prices, Saxenda costs approximately $1,400/month and Wegovy approximately $1,349–$1,430/month — similar pricing. Both are manufactured by Novo Nordisk and have comparable savings programs for commercially insured patients. Out-of-pocket costs depend heavily on insurance coverage, which varies widely. Medicare covers Wegovy under Part D when prescribed for cardiovascular disease risk reduction but has limited obesity drug coverage otherwise. Saxenda is rarely available as a compounded product.

Explore next

Peptides

Guides

Semaglutide dosage guide
Detailed semaglutide dosage chart covering weight management titration (Wegovy), type 2 diabetes dosing (Ozempic), and oral semaglutide (Rybelsus). Includes compounded reconstitution instructions, side effect profiles, and cycle guidance based on published STEP trial data.

More comparisons

Tools